CDC reports 3 new cases this past week, bringing the 2025 total to 1,454 confirmed cases across 42 jurisdictions, with 37 outbreaks.
Weekly measles cases by rash onset date
Image credits: CDC
The CDC reports 1,454 confirmed measles cases in the United States as of September 9, 2025. There have been 37 outbreaks, and 86% of all cases (1,249 of 1,454) are outbreak associated. CDC’s weekly rash-onset graph indicates about three new confirmed cases in the most recent week. This is the lowest weekly count since early January. Counts are preliminary and may change with additional reporting.
Cases have been reported by 42 jurisdictions, including New York City and New York State, totaling 1,433 cases among US residents. An additional 21 cases occurred among international visitors. Hospitalizations have been reported in 12% of cases (180 of 1,454). Three deaths have been reported in 2025.
Most cases are in people who are unvaccinated or have unknown vaccination status (92%). By age group, 28% are younger than 5 years (404 cases), 38% are five to 19 years (554 cases), and 34% are adults 20 years and older (489 cases). Hospitalization proportions by age are 21% in children younger than 5 years, 7% in those ages five to 19 years, and 11% in adults 20 years and older.
Immunity gaps persist, and kindergarten MMR coverage declined to 92.7% in the 2023 to 2024 school year, down from 95.2% in 2019 to 2020, leaving an estimated 280,000 kindergartners at risk. Local pockets of under-immunization continue to drive outbreak potential even where state-level coverage appears high.2
Hospitalizations are 12% with three deaths, and 92% of patients are unvaccinated or have unknown vaccination status.
86% of cases are outbreak associated, comprising 1,433 US residents and 21 international visitors.
MMR coverage of 92.7% among kindergartners leaves about 280,000 children at risk and maintains vulnerability in undervaccinated pockets.
For clinicians, continued vigilance is warranted despite the recent low weekly count. Prioritize MMR catch-up in under-immunized patients, verify immunity before international travel, and consider measles in febrile rash illness, especially among unvaccinated children, travelers, and close contacts.1
Our Summer 2025 feature, Measles 2025, Looking Back and Moving Forward, reviews drivers of resurgence (declining coverage, misinformation, travel), confirms MMR effectiveness (~93% after 1 dose; ~97% after 2), outlines contraindications (moderate–severe immunosuppression; pregnancy), and clarifies care (supportive management; clinician-directed vitamin A in severe pediatric cases).3
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
